A Missing Link in Cancer Clinical Trials: Diverse Populations

Clinical trials for new cancer treatments are most effective when a diverse group of patients participates. Michigan Medicine wants more patients to get involved.

7:00 AM

Author | Kevin Joy

 

Cancer affects everyone, no matter their background or ethnicity.

Yet cancer clinical trials — research studies designed to test the safety and effectiveness of potential new treatments — don't always represent the full scope of the population.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

That's because there is a shortage of diverse clinical trial participants, a deficit that can affect efforts to treat and cure the disease in all patients, no matter their gender, race or ethnicity.

"When we study certain conditions, certain cancers, and we only use one population, we find out a lot about that population," says John M. Carethers, M.D., chair of internal medicine at Michigan Medicine, "but it says nothing about other populations."

For clinical trials to be most effective, diversity is key. Certain types of cancer are more prevalent in black or Hispanic Americans; some cancers behave differently in younger versus older people.

Increasing the number of people involved means researchers could get a clearer handle on how best to help everyone.

Some clinical trials involve comparing two types of treatment or trying a new use for a drug already approved by the Food and Drug Administration for a different cancer. Others involve drugs that are being administered to people for the first time after rigorous laboratory testing.

Each method can help researchers determine if a medication works more effectively than the current standard treatments.

Still, "we won't know until we compare it head-to-head," says Lori Pierce, M.D., a Michigan Medicine radiation oncologist.

SEE ALSO: How Clinical Trials Helped Three Cancer Patients Thrive

She and Carethers know that most patients might have questions about clinical trials.

They also acknowledge that minorities could have particular concerns in light of the Tuskegee syphilis experiment, a federally funded — and highly unethical — study that for 40 years only monitored hundreds of black men with syphilis despite the availability of treatment.

Such wrongdoing, the clinicians stress, is well in the past: "Everyone wants to be cured of their disease," Pierce says. "Clinical trials give everyone equal opportunity to do so."

To learn more about clinical trials at Michigan Medicine, call the Cancer AnswerLine at 1-800-865-1125. 


More Articles About: Cancer Care Cancer Research Health Care Delivery, Policy and Economics Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

MichmedMedia@med.umich.edu

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories
Health Lab
Survivor in Action: A Cancer Patient Lends Her Mind, Body and Voice to Help Others
Participation in clinical trials is one way a mother fights back against cancer. She also volunteers with cancer patients and is working to boost research funds to study her own disease.
hand holding older hand over blanket
Health Lab
What experts wish more people knew about hospice and other end-of-life care
Hospice, palliative care, end-of-life decisions, long-term care insurance and durable power of attorney are all things people with serious health issues should think about.
out the window woman staring
Health Lab
1 in 3 older adults still experience loneliness and isolation
Rates of loneliness and social isolation in older people have declined from pandemic highs, but are still a problem especially for those with mental or physical health issues or disabilities.
patient looking at paper with provider in scrubs blue in clinic
Health Lab
How race impacts patients’ response to cancer immunotherapy
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
bone close up of cells inside green bbble with cells inside in yellow brown pink and red orange background
Health Lab
How breast cancer cells survive in bone marrow after remission
A new study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.
frozen dial with ice on it with red dial
Health Lab
Enzyme identified as new therapeutic target for “cold” tumors
A study identifies an enzyme as a new therapeutic target for “cold” tumors.